Literature DB >> 11835814

[A study of expression of p53, c-myc and PCNA in retinoblastoma].

X Yang1, Z Zhang, Q Zeng.   

Abstract

OBJECTIVE: To investigate the expressions of p53, c-myc (oncogene) and proliferating cell nuclear antigen (PCNA) in retinoblastoma (Rb) and the relationships of the expression to the degree of differentiation and optic nerve infiltration.
METHOD: The expressions of p53, c-myc and PCNA in Rb tissues of 31 cases were analyzed by using LSAB immunohistochemical method.
RESULTS: The positive rates of p53, c-myc and PCNA in Rb were respectively 51.6%, 45.2% and 67.7% and all the expressions were significantly related to the differentiation degree of Rb (all P < 0.05). The expression of PCNA was significantly related to the optic nerve infiltration of Rb (P < 0.05). Both the expressions of p53 and c-myc in Rb were markedly correlated with the expression of PCNA (all P < 0.05).
CONCLUSIONS: The occurrence of Rb is the result of multiple gene mutations. The determinations of p53, c-myc and PCNA are of significance for evaluating the histologic characteristics and biological behavior of Rb.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 11835814

Source DB:  PubMed          Journal:  Zhonghua Yan Ke Za Zhi        ISSN: 0412-4081


  3 in total

1.  High-risk histomorphological features in retinoblastoma and their association with p53 expression: An Indian experience.

Authors:  Rao Seema; Sobti Parul; Khurana Nita
Journal:  Indian J Ophthalmol       Date:  2014-11       Impact factor: 1.848

2.  Molecular pathologic interpretation of new retinoblastoma rosettes.

Authors:  Dipankar Das; Panna Deka; Kasturi Bhattacharjee; Manab Jyoti Barman; Harsha Bhattacharjee; Divakant Misra; Rushil Kumar Saxena; Anusuya Bhattacharyya; Apurba Deka
Journal:  Indian J Ophthalmol       Date:  2017-08       Impact factor: 1.848

3.  Expression of heat shock protein 27 and proliferating cell nuclear antigen in human retinoblastoma.

Authors:  Dongju Qin; Luosheng Tan; Qinghua You; Xiangping Liu
Journal:  Contemp Oncol (Pozn)       Date:  2013-04-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.